Differential activity of rosiglitazone enantiomers at PPAR gamma

D J Parks; N C Tomkinson; M S Villeneuve; S G Blanchard; T M Willson

doi:10.1016/s0960-894x(98)00664-7

Differential activity of rosiglitazone enantiomers at PPAR gamma

Bioorg Med Chem Lett. 1998 Dec 15;8(24):3657-8. doi: 10.1016/s0960-894x(98)00664-7.

Authors

D J Parks¹, N C Tomkinson, M S Villeneuve, S G Blanchard, T M Willson

Affiliation

¹ Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709, USA.

PMID: 9934490
DOI: 10.1016/s0960-894x(98)00664-7

Abstract

Analysis of the enantiomers of rosiglitazone in a PPAR gamma binding assay suggests that the (S)-(-)-isomer is responsible for the antidiabetic activity.

MeSH terms

Hypoglycemic Agents / chemistry
Hypoglycemic Agents / pharmacology*
Receptors, Cytoplasmic and Nuclear / drug effects*
Rosiglitazone
Stereoisomerism
Thiazoles / chemistry
Thiazoles / pharmacology*
Thiazolidinediones*
Transcription Factors / drug effects*

Substances

Hypoglycemic Agents
Receptors, Cytoplasmic and Nuclear
Thiazoles
Thiazolidinediones
Transcription Factors
Rosiglitazone